OraSure Technologies (OSUR) Proxy Filing summary

Executive summary

• Significant operational progress achieved, with a focus on transformation and value creation initiatives as the company approaches key regulatory and commercial milestones in 2026.

• Strategy centers on returning to revenue growth in 2026, driven by stabilization in core markets and new product launches targeting a $2 billion addressable market.

• Operational improvements since 2022 include a 40% workforce reduction, site consolidations, and SG&A expense cuts, resulting in margin expansion and a path toward 50% gross margin.

• Capital allocation remains disciplined, with a $40 million share repurchase program, a debt-free balance sheet, and ongoing investments in R&D and potential acquisitions.

• Leadership demonstrates confidence through significant open-market stock purchases and continued investment under Rule 10b5-1 plans.

Voting matters and shareholder proposals

• Ongoing proxy contest with Altai Capital, which is seeking board representation and advocating for a sale process.

• Multiple settlement offers made, including appointing Altai's nominee John Bertrand as an independent director and proposing board declassification beginning in 2027.

• Altai has rejected all settlement proposals, insisting on board access and representation for its founder.

Board of directors and corporate governance

• Entire board refreshed over the past six years, with three new independent directors added since 2023, bringing healthcare and capital markets expertise.

• John P. Kenny appointed as board chair in October 2025; board includes experienced executives from healthcare and diagnostics sectors.

• Commitment to seek shareholder approval for board declassification at the 2027 annual meeting.